ARDS Aridis Pharmaceuticals Inc.

6.1
0  0%
Previous Close 6.1
Open
Price To Book 5
Market Cap 54,364,585
Shares 8,912,227
Volume 130
Short Ratio
Av. Daily Volume 12,449
Stock charts supplied by TradingView

NewsSee all news

  1. Aridis Pharmaceuticals Appoints Infectious Disease Expert Paul Mendelman, MD as Interim Chief Medical Officer

    SAN JOSE, Calif., Oct. 11, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening

  2. Aridis Pharmaceuticals Executes License Agreement with The Serum Institute of India, Ltd. for Exclusive Rights to Products and Utilization of MabIgX® Platform Technology

    SAN JOSE, Calif., Sept. 30, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat

  3. Aridis Pharmaceuticals to Present AR-105 and AR-501 (Gallium Citrate) Data at IDWeek™ 2019

    SAN JOSE, Calif., Sept. 27, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat

  4. Aridis Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference

    SAN JOSE, Calif., Sept. 27, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat

  5. Aridis Pharmaceuticals to Present at the H.C. Wainwright 21st Annual Global Investment Conference on September 10, 2019

    SAN JOSE, Calif., Sept. 8, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 interim data due 1Q 2020 with final data due late-2020.
AR-301 (Salvecin)
Staphylococcus aureus
Phase 2 trial did not met primary endpoint - September 3, 2019.
AR-105 (Aerucin)
Pseudomonas aeruginosa
Phase 2/3 trial pending AR-105 data.
AR-101 (Aerumab)
Pseudomonas aeruginosa
Phase 1/2 data in healthy subjects due 1Q 2020 and from cystic fibrosis patients in 1Q 2021.
AR-501
Chronic bacterial lung infections in patients with cystic fibrosis (CF)

Latest News

  1. Aridis Pharmaceuticals Appoints Infectious Disease Expert Paul Mendelman, MD as Interim Chief Medical Officer

    SAN JOSE, Calif., Oct. 11, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening

  2. Aridis Pharmaceuticals Executes License Agreement with The Serum Institute of India, Ltd. for Exclusive Rights to Products and Utilization of MabIgX® Platform Technology

    SAN JOSE, Calif., Sept. 30, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat

  3. Aridis Pharmaceuticals to Present AR-105 and AR-501 (Gallium Citrate) Data at IDWeek™ 2019

    SAN JOSE, Calif., Sept. 27, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat

  4. Aridis Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference

    SAN JOSE, Calif., Sept. 27, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat

  5. Aridis Pharmaceuticals to Present at the H.C. Wainwright 21st Annual Global Investment Conference on September 10, 2019

    SAN JOSE, Calif., Sept. 8, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening

  6. Aridis Pharmaceuticals Reports Phase 2 Clinical Trial Results of AR-105 for the Treatment of Ventilator-Associated Pneumonia Caused by Pseudomonas Aeruginosa

    SAN JOSE, Calif., Sept. 3, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening